MYD88 and neoplasm: Studies have shown that the gut microbiota could stimulate tumor-infiltrating myeloid cells to produce ROS through the TLR4-MYD88 signaling pathway, which increased the anti-tumor efficacy of oxaliplatin in mice bearing colon cancer.